

CORRECTION

Correction: Rapid enteric testing to permit targeted antimicrobial therapy, with and without *Lactobacillus reuteri* probiotics, for paediatric acute diarrhoeal disease in Botswana: A pilot, randomized, factorial, controlled trial

Jeffrey M. Pernica, Andrew P. Steenhoff, Margaret Mokomane, Banno Moorad, Kwana Lechiile, Marek Smieja, Loeto Mazhani, Ji Cheng, Matthew S. Kelly, Mark Loeb, Ketil Stordal, David M. Goldfarb

The dose of *Lactobacillus reuteri* DSM 17938 appears incorrectly throughout the article as 5×10^8 colony-forming units (cfu) per day. The correct dose of *Lactobacillus reuteri* DSM 17938 should be 1×10^8 cfu per day.

Reference

- Pernica JM, Steenhoff AP, Mokomane M, Moorad B, Lechiile K, Smieja M, et al. (2017) Rapid enteric testing to permit targeted antimicrobial therapy, with and without *Lactobacillus reuteri* probiotics, for paediatric acute diarrhoeal disease in Botswana: A pilot, randomized, factorial, controlled trial. PLoS ONE 12(10): e0185177. <https://doi.org/10.1371/journal.pone.0185177> PMID: 28991918



OPEN ACCESS

Citation: Pernica JM, Steenhoff AP, Mokomane M, Moorad B, Lechiile K, Smieja M, et al. (2018) Correction: Rapid enteric testing to permit targeted antimicrobial therapy, with and without *Lactobacillus reuteri* probiotics, for paediatric acute diarrhoeal disease in Botswana: A pilot, randomized, factorial, controlled trial. PLoS ONE 13(3): e0194957. <https://doi.org/10.1371/journal.pone.0194957>

Published: March 21, 2018

Copyright: © 2018 Pernica et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.